Navigation Links
EPHB2 as a New Potential Therapeutic Target for Mesothelioma
Date:7/31/2013

Alexandria, VA (PRWEB) July 31, 2013

Last week, the Journal of Thoracic Oncology published the results of a study looking into the overexpression of the ephrin B2 receptor (EPHB2) in patients with mesothelioma. The researchers at the New York University Langone Medical Center observed that EPHB2 is overexpressed in all malignant mesothelioma cell lines, but not in benign mesothelial cells. In addition, they found that silencing this receptor resulted in a significant increase in certain processes responsible for naturally ridding the body of old and defective cells (including cancerous ones).

The team of researchers who worked on this study includes Dr. Harvey Pass, one of the founders and a former board member of the Mesothelioma Applied Research Foundation. Dr. Pass has been a leader in the field of mesothelioma and a vocal advocate for mesothelioma patients.

“The mesothelioma community is looking for novel targets for therapy, and the data on the ephrins may provide an opportunity for this,” said Dr. Pass. “Certainly we also must expand our findings to elucidate the prognostic and predictive characteristics of this important pathway,” he added.

Through this study, Dr. Pass and his team concluded that EPHB2 could serve as a potential novel therapeutic target for treatment of mesothelioma, a disease that, currently, has only one FDA-approved treatment and a median survival of 12 months.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. Approximately 3,000 Americans are diagnosed with mesothelioma every year and an estimated one-third were exposed while serving in the Navy or working in Navy shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by it. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish more effective treatments for mesothelioma and, ultimately, a cure for this rare, but extremely aggressive, cancer. To date, the Foundation has awarded over $8.2 million to research.

More information is available at http://www.curemeso.org.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10985987.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Potential Dangers of Diet Soda Article and Video Released by Health News Wires
2. Stem cells in urine easy to isolate and have potential for numerous therapies
3. Study predicts potential surge in medically-attended injuries
4. TRICARE CRISIS: QmedRx Spotlights Potential Resolution to Budgetary Dilemma
5. Researchers find potential new target to treat malignant pleural mesothelioma
6. Monroe, CT Gum Disease Treatment Can Now Potentially Reduce the Risk of Tooth Loss with the Use of the FDA-cleared Laser by Dr. Richard Amato
7. Victory Pain Center Weighs in on Potential Risks of Steroid Injections
8. Is there a "Code" To Crack For Permanent Weight Loss? Best-Selling Author Jennifer Nicole Lee Says Yes in Her Book "Crack The Code: Unlock Your Fat Burning & Weight Loss Potential"
9. Study finds potential markers for severity of childhood arthritis
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Detox Formula, Designed to Cleanse the Liver of Potentially Dangerous Toxins During Dieting
11. New Program Designed For the Best Weight Loss and Potential Reduction in Health Insurance Costs Now Available From Diet Doc hCG Diets & Weight Loss Plans / hCGTreatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: